{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=34",
    "query": {
      "intervention": "Saline 0.9%",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 1514,
    "total_pages": 152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T17:46:02.153Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01072357",
      "title": "Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corneal Neovascularization",
        "Corneal Graft Failure"
      ],
      "interventions": [
        {
          "name": "Avastin® (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "0.9% NaCl & Refresh Liquigel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reza Dana, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-12",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072357"
    },
    {
      "nct_id": "NCT06216886",
      "title": "OnabotulinumtoxinA for Trigeminal Neuralgia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 100 UNT [Botox]",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9% for Injection, Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-06-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216886"
    },
    {
      "nct_id": "NCT00805818",
      "title": "Study of NNZ-2566 in Patients With Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Injuries"
      ],
      "interventions": [
        {
          "name": "NNZ-2566",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuren Pharmaceuticals Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 261,
      "start_date": "2010-04",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 20,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805818"
    },
    {
      "nct_id": "NCT03999996",
      "title": "Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "63 Years",
        "sex": "ALL",
        "summary": "13 Years to 63 Years"
      },
      "enrollment_count": 365,
      "start_date": "2019-11-12",
      "completion_date": "2024-05-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 8,
      "location_summary": "Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Richfield",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999996"
    },
    {
      "nct_id": "NCT04478994",
      "title": "A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "TEPEZZA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2021-11-17",
      "completion_date": "2022-12-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478994"
    },
    {
      "nct_id": "NCT00262613",
      "title": "Sodium Pyruvate Therapy in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "sodium pyruvate in 0.9% sodium chloride solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emphycorp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 60,
      "start_date": "2004-09",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2006-05-29",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 2,
      "location_summary": "New Britain, Connecticut • New Haven, Connecticut",
      "locations": [
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262613"
    },
    {
      "nct_id": "NCT03549520",
      "title": "CEUS Evaluation of Hypoxic Ischemic Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypoxic-Ischemic Encephalopathy",
        "Brain Ischemia Hypoxia"
      ],
      "interventions": [
        {
          "name": "Sulfur hexafluoride lipid-type A microspheres",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "18 Months",
        "sex": "ALL",
        "summary": "1 Minute to 18 Months"
      },
      "enrollment_count": 1,
      "start_date": "2020-12-01",
      "completion_date": "2024-05-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03549520"
    },
    {
      "nct_id": "NCT03140488",
      "title": "Oxytocin Dosage to Decrease Induction Duration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "Labor, Induced",
        "Oxytocin"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2017-06-05",
      "completion_date": "2019-09-05",
      "has_results": true,
      "last_update_posted_date": "2022-12-20",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140488"
    },
    {
      "nct_id": "NCT02823106",
      "title": "Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Verapamil and Citicoline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Justin Fraser",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-08",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823106"
    },
    {
      "nct_id": "NCT04501978",
      "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "LY3819253",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VIR-7831",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196/BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MP0420",
          "type": "DRUG"
        },
        {
          "name": "PF-07304814",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2753,
      "start_date": "2020-08-04",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-10-24T17:46:02.153Z",
      "location_count": 98,
      "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501978"
    }
  ]
}